These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33483215)

  • 41. Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheria-tetanus-acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination.
    Rennels MB; Englund JA; Bernstein DI; Losonsky GA; Anderson EL; Pichichero ME; Munoz FM; Wolff MC
    Pediatr Infect Dis J; 2000 May; 19(5):417-23. PubMed ID: 10819337
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
    Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L;
    Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
    Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/H. influenzae type b combination vaccines.
    Schmitt HJ; von Kries R; Hassenpflug B; Hermann M; Siedler A; Niessing W; Clemens R; Weil J
    Pediatr Infect Dis J; 2001 Aug; 20(8):767-74. PubMed ID: 11734739
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevention of pertussis across the age spectrum through the use of the combination vaccines PENTACEL and ADACEL.
    Halperin SA
    Expert Opin Biol Ther; 2006 Aug; 6(8):807-21. PubMed ID: 16856802
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age.
    Carlsson RM; Claesson BA; Selstam U; Fagerlund E; Granström M; Blondeau C; Hoffenbach A
    Pediatr Infect Dis J; 1998 Nov; 17(11):1026-33. PubMed ID: 9849987
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with Diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines in children 15 months of age.
    Trofa AF; Klein NP; Paul IM; Michaels MG; Goessler M; Chandrasekaran V; Blatter M
    Pediatr Infect Dis J; 2011 Sep; 30(9):e164-9. PubMed ID: 21494175
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Waning protection following 5 doses of a 3-component diphtheria, tetanus, and acellular pertussis vaccine.
    Klein NP; Bartlett J; Fireman B; Aukes L; Buck PO; Krishnarajah G; Baxter R
    Vaccine; 2017 Jun; 35(26):3395-3400. PubMed ID: 28506516
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Uberall MA; Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; Laussucq S; Eckhardt T
    Dev Biol Stand; 1997; 89():83-9. PubMed ID: 9272335
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Improved serologic responses to DTaP over Tdap vaccination in adult hematopoietic cell transplant recipients.
    Xu B; Gordillo CA; Delille EM; Malandrakis S; Assal A; Mapara MY; Reshef R
    Eur J Haematol; 2023 Sep; 111(3):499-505. PubMed ID: 37365676
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of acellular pertussis-tetanus-diphtheria vaccines and whole-cell pertussis-tetanus-diphtheria vaccines in infancy.
    Korkmaz HA; Aydin A; Unal B
    Paediatr Int Child Health; 2014 Aug; 34(3):198-202. PubMed ID: 24621240
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers.
    Wanlapakorn N; Maertens K; Thongmee T; Srimuan D; Thatsanathorn T; Van Damme P; Leuridan E; Poovorawan Y
    Vaccine; 2020 Oct; 38(44):6914-6921. PubMed ID: 32888740
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Infant immunization with acellular pertussis vaccines in the United States: assessment of the first two years' data from the Vaccine Adverse Event Reporting System (VAERS).
    Braun MM; Mootrey GT; Salive ME; Chen RT; Ellenberg SS
    Pediatrics; 2000 Oct; 106(4):E51. PubMed ID: 11015546
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Magnitude of interference after diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b capsular polysaccharide-tetanus vaccination is related to the number of doses administered.
    Daum RS; Zenko CE; Given GZ; Ballanco GA; Parikh H; Germino K
    J Infect Dis; 2001 Nov; 184(10):1293-9. PubMed ID: 11679918
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines.
    Tozzi AE; Anemona A; Stefanelli P; Salmaso S; Ciofi degli Atti ML; Mastrantonio P; Giammanco A;
    Pediatrics; 2001 Feb; 107(2):E25. PubMed ID: 11158499
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association between undervaccination with diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine and risk of pertussis infection in children 3 to 36 months of age.
    Glanz JM; Narwaney KJ; Newcomer SR; Daley MF; Hambidge SJ; Rowhani-Rahbar A; Lee GM; Nelson JC; Naleway AL; Nordin JD; Lugg MM; Weintraub ES
    JAMA Pediatr; 2013 Nov; 167(11):1060-4. PubMed ID: 24019039
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
    Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study.
    John T; Voysey M; Yu LM; McCarthy N; Baudin M; Richard P; Fiquet A; Kitchin N; Pollard AJ
    Vaccine; 2015 Aug; 33(36):4579-85. PubMed ID: 26165918
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Incidence rates of health outcomes of interest among Chinese children exposed to selected vaccines in Yinzhou Electronic Health Records: A population-based retrospective cohort study.
    Huang K; Tao S; Zhou X; Mo J; Zhu B; Shen P; Lin H; Arena PJ; He N
    Vaccine; 2020 Apr; 38(18):3422-3428. PubMed ID: 32178909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.